# Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP)

## Background

- HAP: Pneumonia that develops \>48 hours after admission

- VAP: Pneumonia that develops \>48 hours after endotracheal
    intubation

## Evaluation

- Cultures of blood, sputum, endotracheal aspirate and/or bronchoscopy
    specimen

- Consider MRSA nares to help with de-escalation

- If there is concern for respiratory viruses: send influenza, COVID,
    RVP

## Management

- Initially cover for MRSA and *Pseudomonas*

- Antibiotic Duration: 7 days in uncomplicated cases, although
    specific pathogens (e.g., *Pseudomonas*) may require longer duration
    and ID guidance

- Consider ID consultation if the patient is not clinically improving
    on empiric therapy or if an MDR pathogen grows from culture

- If no MRSA isolated and pt is improving, consider stopping
    vancomycin ASAP

- There is concern for nephrotoxicity with combination Vancomycin and
    piperacillin-tazobactam, but data controversial

<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 34%" />
<col style="width: 49%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>MRSA Coverage</p>
</blockquote></th>
<th><blockquote>
<p>Pseudomonas Coverage</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>First Line</td>
<td>Vancomycin (Pharmacy dosing)</td>
<td>Cefepime 2g q8h OR Piperacillin-tazobactam 3.375 q8h extended
infusion OR Ceftazidime 2g q8h</td>
</tr>
<tr class="even">
<td>Alternative</td>
<td>Vancomycin allergy: Linezolid 600 mg PO q12h</td>
<td>True PCN allergy: Aztreonam 2g q8h</td>
</tr>
</tbody>
</table>
